Related references
Note: Only part of the references are listed.Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study
Terry Golombick et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
HAEMATOLOGICAL CANCER Redefining myeloma
S. Vincent Rajkumar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Diagnosis of Smoldering Multiple Myeloma
S. Vincent Rajkumar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future
Adam J. Waxman et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R. A. Kyle et al.
LEUKEMIA (2010)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
John A. Lust et al.
MAYO CLINIC PROCEEDINGS (2009)
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Bart Barlogie et al.
BLOOD (2008)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri et al.
BLOOD (2008)
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Pellegrino Musto et al.
CANCER (2008)
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system
C. L. H. Snozek et al.
LEUKEMIA (2008)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Perez-Persona et al.
BLOOD (2007)
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
Frits van Rhee et al.
BLOOD (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Diagnostic performance of quantitative κ and λ free light chain assays in clinical practice
JA Katzmann et al.
CLINICAL CHEMISTRY (2005)
Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance
SV Rajkumar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
HJ Lachmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Thalidomide as initial therapy for early-stage myeloma
SV Rajkumar et al.
LEUKEMIA (2003)
Serum test for assessment of patients with Bence Jones myeloma
AR Bradwell et al.
LANCET (2003)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma
M Drayson et al.
BLOOD (2001)
Share Paper
